AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04873479
Drug: S-ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
Trial: NCT06182592
Drug: Liposomal cytarabine-daunorubicin for injection
RxNorm normalized name: cytarabine / daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
Trial: NCT06182592
Drug: 7+3 (cytarabine and daunorubicin)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1, 2, and 3.~Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.~Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.
Trial: NCT04114890
Drug: Tenofovir Disoproxil Fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
Trial: NCT05590013
Drug: Pectointercostal and ESP block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
Trial: NCT05181683
Drug: Casirivimab+Imdevimab
RxNorm normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
Trial: NCT04976751
Drug: Percutaneous electrical nerve stimulation treatment
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using the percutaneous electrical nerve stimulation instrument to different points of the body
Trial: NCT06258356
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: novel ultra-short-acting benzodiazepine-like anesthetic.
Trial: NCT05933395
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
Trial: NCT05933395
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Trial: NCT05933395
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Trial: NCT05933395
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
Trial: NCT05933395
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
Trial: NCT04473924
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Body surface area-based dosing of mycophenolate
Trial: NCT04473924
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard (fixed) dosing of mycophenolate
Trial: NCT05462548
Drug: Luspatercept Injectable Product
RxNorm normalized name: luspatercept Injectable Product
DrugBank: Luspatercept (DB12281)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1-1.25mg/kg every 3 weeks subcutaneous injection
Trial: NCT06077786
Drug: Lu AG06474
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT06077786
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule
Trial: NCT05323981
Drug: Perjeta
RxNorm normalized name: Perjeta
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous drip of 420mg PERJETA
Trial: NCT04997161
Drug: Sodium Zirconium Cyclosilicate (SZC)
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
Trial: NCT05845723
Drug: tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
Trial: NCT05845723
Drug: tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
Trial: NCT05192369
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: CTP-543 12 mg (1 x 12 mg tablet), dosed with water
Trial: NCT05192369
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: CTP-543 48 mg (4 x 12 mg tablet) dosed with water
Trial: NCT05192369
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (1 x 400 mg tablet) dosed with water
Trial: NCT06505369
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab will be administered by SC injection
Trial: NCT06505369
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib will be administered by SC injection
Trial: NCT06505369
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered by oral route
Trial: NCT06505369
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered by oral route
Trial: NCT06505369
Drug: Talquetamab
RxNorm normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talquetamab will be administered by SC injection
Trial: NCT06505369
Drug: Teclistamab
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab will be administered by SC injection
Trial: NCT05365178
Drug: Fulvestrant injection
RxNorm normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
Trial: NCT06254404
Drug: Low dose protamine
RxNorm normalized name: protamines
DrugBank: Protamine sulfate (DB09141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 70% of the normal dose of protamine
Trial: NCT05564429
Drug: 18F-SF12051
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected intravenously followed by PET scanning
Trial: NCT05392959
Drug: Dapagliflozin 10 mg Tab
RxNorm normalized name: dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg per day
Trial: NCT06321887
Drug: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).
Trial: NCT06321887
Drug: Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).
Trial: NCT06321887
Drug: Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
Trial: NCT04702685
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anesthetic for injection
Trial: NCT06562920
Drug: adebrelimab and chemotherapy
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
Trial: NCT06170723
Drug: BMS-986368
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06170723
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06170723
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04941313
Drug: 3D229
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3D229 is an investigational drug.
Trial: NCT05028478
Drug: CN202
RxNorm normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
Trial: NCT05912335
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
Trial: NCT04840472
Drug: 111I-n panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imaging Agent
Trial: NCT01549548
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: NCT06188546
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
Trial: NCT06446557
Drug: treatment adaptation guided by ctDNA variation
DrugBank: DAPTA (DB16290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after 4 cycles of doublet + TA, non-progressive patients will be allocated to a strategy according to ctDNA value and variation from C1-C3: Arm A1: CT discontinuation (ctDNA normalization \< 0.1 ng/ml or ctDNA not detectable) Arm A2 : maintenance with fluoropyrimidine + TA (ctDNA ≥ 0.1 ng/ml and ∆ctDNA≥ 80%).~Arm A3 : ctDNA non-responders (∆ctDNA \< 80% or increase) : switch of CT +/- TA.
Trial: NCT00939835
Drug: Citalopram Hydrobromide
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05691855
Drug: 89Zr-NY009
RxNorm normalized name: 89ZR-BEVACIZUMAB
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
Trial: NCT04659304
Drug: Allocetra-OTS
RxNorm normalized name: Allocetra
DrugBank: Allocetra (DB16424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
Trial: NCT04943549
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
Trial: NCT04937088
Drug: ASA
RxNorm normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid aspirin formulation
Trial: NCT05428826
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
Trial: NCT06393530
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
Trial: NCT06393530
Drug: 0.2% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
Trial: NCT05849389
Drug: Vosoritide
RxNorm normalized name: VOSORITIDE
DrugBank: Vosoritide (DB11928)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
Trial: NCT06018116
Drug: Bicalutamide 150 mg
RxNorm normalized name: bicalutamide 150 MG
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nonsteroidal antiandrogen
Trial: NCT05356091
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
Trial: NCT05356091
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
Trial: NCT05275699
Drug: 68Ga-FAPI
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
Trial: NCT00113958
Drug: Cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06014424
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
Trial: NCT05429463
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
Trial: NCT05429463
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Trial: NCT00002356
Drug: Fomivirsen sodium
RxNorm normalized name: Fomivirsen Sodium
DrugBank: Fomivirsen (DB06759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000938
Drug: ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05103345
Drug: SGN1
RxNorm normalized name: Sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
Trial: NCT05404490
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Trial: NCT06596772
Drug: MB04 (proposed biosimilar to etanercept)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MB04 50 mg/week via subcutaneous injection
Trial: NCT06596772
Drug: Enbrel (etanercept)
RxNorm normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Enbrel 50 mg/week via subcutaneous injection
Trial: NCT06756191
Drug: Combination therapy group
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
Trial: NCT06756191
Drug: Liposomal Amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (AmBisome®) alone
Trial: NCT05449704
Drug: DA-5218
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (DA-5218 one tablet once a day)
Trial: NCT05449704
Drug: DA-5218-R1 + DA-5218-R2 + DA-5218-R3
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)
Trial: NCT04892420
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.
Trial: NCT04892420
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
Trial: NCT04892420
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
Trial: NCT04892420
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
Trial: NCT04540094
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any preparation of 5% Human Albumin Solution which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study
Trial: NCT02399462
Drug: Acthar
RxNorm normalized name: Acthar
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly\* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly\* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly\* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly\* Weeks 27 through 28~\*Injections are to be spaced 72-96 hours apart (+/-6 hours).